Main competitors
Add to a list
1m. EPS revision 1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Divergence of Estimates Nbr of analysts
6
26
22
22
27
19
24
19
20
26
22
22
21
26
19
15
18
17
17
Average 20
Weighted average by Cap. 23
Other Pharmaceuticals